Background: Chronic infections and associated inflammatory markers are suggested risk factors for cardiovascular diseases (CVD) and stroke. The proinflammatory cytokine interleukin (IL)-1β is suggested to play a role in the regulation of local inflammatory responses in both CVD and periodontitis. The leukotoxin from the periodontal pathogen Actinobacillus actinomycetemcomitans has recently been shown to cause abundant secretion of IL-1β from macrophages. The aim of the present study was to compare the prevalence of systemic antibodies to A. actinomycetemcomitans leukotoxin in stroke cases (n = 273) and matched controls (n = 546) in an incident case-control study nested within the Northern Sweden MONICA and Västerbotten Intervention cohorts. Methods: Antibodies to A. actinomycetemcomitans leukotoxin were analyzed in a bioassay with HL-60 cells (leukocytes), purified A. actinomycetemcomitans leukotoxin, and plasma. Plasma samples which inhibited lactate dehydrogenase release from leukotoxin-lysed cells by ≧50% were classified as antibody positive. Results: Antibodies to A. actinomycetemcomitans leukotoxin were detected in 18.8% of the women and 15.2% of the men. Women with those antibodies had a significantly decreased risk for stroke (OR = 0.28, 95% CI: 0.13–0.59), but not men (OR = 0.88, 95% CI: 0.52–1.51). Conclusion: The immunoreactivity to A. actinomycetemcomitans leukotoxin correlates negatively with a future stroke in woman, but not in men. Further studies are needed to explain the underlying mechanisms, as well as the biological relevance of this finding.

Keywords:
Actinobacillus actinomycetemcomitans, Leukotoxin, Antibodies, Stroke
1.
Lindsberg PJ, Grau AJ: Inflammation and infections as risk factors for ischemic stroke. Stroke 2003;34:2518–2532.
2.
Emsley HC, Tyrrell PJ: Inflammation and infection in clinical stroke. J Cereb Blood Flow Metab 2002;22:1399–1419.
3.
Blake GJ, Ridker PM: Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002;252:283–294.
4.
Ross R: Atherosclerosis is an inflammatory disease. Am Heart J 1999;138:S419–S420.
5.
Epstein SE, Zhou YF, Zhu J: Infection and atherosclerosis: emerging mechanistic paradigms. Circulation 1999;100:20–28.
6.
Grau AJ, Buggle F, Ziegler C, Schwarz W, Meuser J, Tasman AJ, Buhler A, Benesch C, Becher H, Hacke W: Association between acute cerebrovascular ischemia and chronic and recurrent infection. Stroke 1997;28:1724–1729.
7.
Mattila KJ, Valtonen VV, Nieminen MS, Asikainen S: Role of infection as a risk factor for atherosclerosis, myocardial infarction, and stroke. Clin Infect Dis 1998;26:719–734.
8.
Genco R, Offenbacher S, Beck J: Periodontal disease and cardiovascular disease: epidemiology and possible mechanisms. J Am Dent Assoc 2002;133:S14–S22.
9.
Scannapieco FA, Bush RB, Paju S: Associations between periodontal disease and risk for atherosclerosis, cardiovascular disease, and stroke. A systematic review. Ann Periodontol 2003;8:38–53.
10.
Muhlestein JB: Chronic infection and coronary artery disease. Med Clin North Am 2000;84:123–148.
11.
Prasad A, Zhu J, Halcox JP, Waclawiw MA, Epstein SE, Quyyumi AA: Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation 2002;106:184–190.
12.
Mombelli A: Periodontitis as an infectious disease: specific features and their implications. Oral Dis 2003;9:S6–S10.
13.
Beck JD, Pankow J, Tyroler HA, Offenbacher S: Dental infections and atherosclerosis. Am Heart J 1999;138:S528–S533.
14.
Loesche WJ, Schork A, Terpenning MS, Chen YM, Kerr C, Dominguez BL: The relationship between dental disease and cerebral vascular accident in elderly United States veterans. Ann Periodontol 1998;3:161–174.
15.
Henderson B, Nair SP, Ward JM, Wilson M: Molecular pathogenicity of the oral opportunistic pathogen Actinobacillus actinomycetemcomitans. Annu Rev Microbiol 2003;57:29–55.
16.
Welch RA: RTX toxin structure and function: a story of numerous anomalies and few analogies in toxin biology. Curr Top Microbiol Immunol 2001;257:85–111.
17.
Lally ET, Hill RB, Kieba IR, Korostoff J: The interaction between RTX toxins and target cells. Trends Microbiol 1999;7:356–361.
18.
Johansson A, Claesson R, Hänström L, Sandström G, Kalfas S: Polymorphonuclear leukocyte degranulation induced by leukotoxin from Actinobacillus actinomycetemcomitans. J Periodont Res 2000;35:85–92.
19.
Mangan DF, Taichman NS, Lally ET, Wahl SM: Lethal effects of Actinobacillus actinomycetemcomitans leukotoxin on human T lymphocytes. Infect Immun 1991;59;3267–3272.
20.
Yamaguchi N, Kubo C, Masuhiro Y, Lally ET, Koga T, Hanazawa S: Tumor necrosis factor alpha enhances Actinobacillus actinomycetemcomitans leukotoxin-induced HL-60 cell apoptosis by stimulating lymphocyte function-associated antigen 1 expression. Infect Immun 2004;72:269–276.
21.
Kelk P, Johansson A, Claesson R, Hänström L, Kalfas S: Caspase 1 involvement in human monocyte lysis induced by Actinobacillus actinomycetemcomitans leukotoxin. Infect Immun 2003;71:4448–4455.
22.
Kelk P, Claesson R, Hänström L, Lerner UH, Kalfas S, Johansson A: Abundant secretion of bioactive IL-1β by human macrophages induced by Actinobacillus actinomycetemcomitans leukotoxin. Infect Immun 2005;73:453–458.
23.
Loppnow H, Westphal E, Buchhorn R, Wessel A, Werdan K: Interleukin-1 and related proteins in cardiovascular disease in adults and children. Shock 2001;16:3–9.
24.
Boch JA, Wara-Aswapati N, Auron PE: Interleukin 1 signal transduction – Current concepts and relevance to periodontitis. J Dent Res 2001;80:400–407.
25.
Touzani O, Boutin H, LeFeuvre R, Parker L, Miller A, Luheshi G, Rothwell N: Interleukin-1 influences ischemic brain damage in the mouse independently of the interleukin-1 type I receptor. J Neurosci 2002;22:38–43.
26.
Patel HC, Boutin H, Allan SM: Interleukin-1 in the brain: mechanisms of action in acute neurodegeneration. Ann N Y Acad Sci 2003;992:39–47.
27.
Haraszthy VI, Zambon JJ, Trevisan M, Zeid M, Genco RJ: Identification of periodontal pathogens in atheromatous plaques. J Periodontol 2000;71:1554–1560.
28.
Ishihara K, Nabuchi A, Ito R, Miyachi K, Kuramitsu HK, Okuda K: Correlation between detection rates of periodontopathic bacterial DNA in carotid coronary stenotic artery plaque and in dental plaque samples. J Clin Microbiol 2004;42:1313–1315.
29.
Tunstall-Pedoe H, for the WHO MONICA Project: The World Health Organization MONICA Project (monitoring of trends and determinants in cardiovascular diseases): a major international collaboration. J Clin Epidemiol 1988;41:105–114.
30.
Hallmans G, Agren A, Johansson G, Johansson A, Stegmayr B, Jansson JH, Lindahl B, Rolandsson O, Soderberg S, Nilsson M, Johansson I, Weinehall L: Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort – Evaluation of risk factors and their interactions. Scand J Public Health 2003;61:S18–S24.
31.
Stegmayr B, Lundberg V, Asplund K: The events registration and survey procedures in the Northern Sweden MONICA Project. Scand J Public Health 2003;61:S9–S17.
32.
Stegmayr B, Asplund K: Measuring stroke in the population: quality of routine statistics in comparison with a population-based stroke registry. Neuroepidemiology 1992;11:204–213.
33.
Weinehall L: Partnership for Health. On the Role of Primary Health Care in a Community Intervention Programme; thesis, Umeå, 1997, new series No 531.
34.
Lally ET, Kieba IR, Sato A, Green CL, Rosenbloom J, Korostoff J, Wang JF, Shenker BJ, Ortlepp S, Robinson MK, Billings PC: RTX toxins recognize a beta2 integrin on the surface of human target cells. J Biol Chem 1997;272:30463–30469.
35.
Johansson A, Hänström L, Kalfas S: Inhibition of Actinobacillus actinomycetemcomitans leukotoxicity by bacterial proteases. Oral Microbiol Immunol 2000;15:218–225.
36.
Desvarieux M, Schwahn C, Volzke H, Demmer RT, Ludemann J, Kessler C, Jacobs DR Jr, John U, Kocher T: Gender differences in the relationship between periodontal disease, tooth loss, and atherosclerosis. Stroke 2004;35:2029–2035.
37.
Hyman JJ, Rams TE, Albandar JM, Adesanya MR, Winn DM, Ebersole JL: Porphyromonas gingivalis and Actinobacillus actinomycetemcomitans serum IgG antibody responses in United States population. IADR, San Diego, 2002, abstract 2699.
38.
Asikainen S, Chen C: Oral ecology and person-to-person transmission of Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis. Periodontol 2000 1999;20:65–81.
39.
van Winkelhoff AJ, Slots J: Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in nonoral infections. Periodontol 2000 1999;20:122–135.
40.
Kinane DF, Mooney J, Ebersole JL: Humoral immune response to Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in periodontal disease. Periodontol 2000 1999;20:289–340.
41.
Schenkein HA, Berry CR, Purkall D, Burmeister JA, Brooks CN, Tew JG: Phosphorylcholine-dependent cross-reactivity between dental plaque bacteria and oxidized low-density lipoproteins. Infect Immun 2001;69:6612–6617.
42.
Strle K, Zhou JH, Shen WH, Broussard SR, Johnson RW, Freund GG, Dantzer R, Kelley KW: Interleukin-10 in the brain. Crit Rev Immunol 2001;21:427–449.
43.
Buhlin K, Gustafsson A, Pockley AG, Frostegard J, Klinge B: Risk factors for cardiovascular disease in patients with periodontitis. Eur Heart J 2003;24:2099–2107.
44.
Joshipura KJ, Wand HC, Merchant AT, Rimm EB: Periodontal disease and biomarkers related to cardiovascular disease. J Dent Res 2004;83:151–155.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.